Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World

Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World

Iguratimod (IGU) is a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) routinely prescribed in Japan since 2012 to patients with rheumatoid arthritis (RA). Iguratimod acts directly on B cells by inhibiting the production of inflammatory cytokines (tumor necrosis factor-α, inter...

Full description

Bibliographic Details
Main Author:	Yuji Nozaki
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	Life
Subjects:	iguratimod csDMARD rheumatoid arthritis
Online Access:	https://www.mdpi.com/2075-1729/11/5/457

Similar Items

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
by: Mark C. Genovese, et al.
Published: (2020-06-01)

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis
by: Borja Hernández-Breijo, et al.
Published: (2019-02-01)

Safety and efficacy of an Anti-CD20 Monoclonal antibody (RedituxTM) In Indian patients with seropositive rheumatoid arthritis
by: Arun Hegde, et al.
Published: (2018-01-01)

Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
by: Ruediger B. Mueller, et al.
Published: (2019-03-01)

Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial
by: Matthijs S. van der Leeuw, et al.
Published: (2020-04-01)

The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care
by: Asuka Inoue, et al.
Published: (2020-10-01)

How to reduce costs of biological treatments in patients with Rheumatoid Arthritis: The Dutch experience
by: Piet L.C.M. van Riel
Published: (2016-01-01)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
by: Mysler E, et al.
Published: (2021-06-01)

Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
by: Sisi Xie, et al.
Published: (2020-02-01)

Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
by: Sisi Xie, et al.
Published: (2020-04-01)

Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs
by: Chao-Jun Hu, et al.
Published: (2021-07-01)

Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
by: Basant Kumar Maheshwari
Published: (2018-01-01)

Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
by: Cédric Lukas, et al.
Published: (2019-11-01)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
by: Vandana Bhushan, et al.
Published: (2021-09-01)

Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis
by: Thomas Wilke, et al.
Published: (2017-08-01)

Safety and efficacy of newer biologics DMARDs in the management of rheumatoid arthritis: A systematic review
by: Basiru Ahmad Zago, et al.
Published: (2020-12-01)

The Efficacy and Safety of Mainstream Medications for Patients With cDMARD-Naïve Rheumatoid Arthritis: A Network Meta-Analysis
by: Weiyan Cai, et al.
Published: (2018-03-01)

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
by: Soo-Kyung Cho, et al.
Published: (2017-12-01)

DMARDs–Gut Microbiota Feedback: Implications in the Response to Therapy
by: Oscar Zaragoza-García, et al.
Published: (2020-10-01)

Rheumatoid arthritis
by: Yoshiya Tanaka
Published: (2020-09-01)

CORRELATIONS BETWEEN SYSTEMIC THERAPY WITH CONVENTIONAL (SYNTHETIC) AND BIOLOGICAL DMARDS, RHEUMATOID ARTHRITIS AND PERIODONTAL INDICES OF CHRONIC PERIODONTITIS
by: Maria Alexandra Martu, et al.
Published: (2019-01-01)

Management of rheumatoid arthritis during pregnancy: challenges and solutions
by: Krause ML, et al.
Published: (2016-03-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
by: Alvin F. Wells, et al.
Published: (2019-05-01)

The importance of early arthritis in patients with rheumatoid arthritis
by: Georgiana Iftimie, et al.
Published: (2018-10-01)

Rheumatoid arthritis and lymphoma: the role of disease-modifying anti-rheumatic drugs
by: Detrick, Jordan
Published: (2018)

Clinical and Laboratory Associations with Methotrexate Metabolism Gene Polymorphisms in Rheumatoid Arthritis
by: Leon G. D’Cruz, et al.
Published: (2020-09-01)

The Use of Tocilizumab in Combination with Methotrexate in Indonesian Rheumatoid Arthritis Patients (PICTURE INA Study)
by: Bambang Setyohadi, et al.
Published: (2018-06-01)

Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
by: Akhlaghi S, et al.
Published: (2018-10-01)

Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis
by: Yannick Degboé, et al.
Published: (2020-06-01)

Rheumatoid Arthritis-associated Interstitial Lung Disease in Greece: A Multicentre Epidemiological and Clinical Study
by: Theofanis Karageorgas, et al.
Published: (2018-01-01)

Molecular mechanisms and clinical application of Iguratimod: A review
by: Huihui Jiang, et al.
Published: (2020-02-01)

BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study
by: Fiona Rayner, et al.
Published: (2021-07-01)

Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview
by: Yoshiya Tanaka
Published: (2021-03-01)

Investigation of the plasma levels of CCL-17 and CCL-25 and their receptor gene expression in rheumatoid arthritis patients
by: Zahra Samimi, et al.
Published: (2019-07-01)

Investigation of the plasma levels of CCL-17 and CCL-25 and their receptor gene expression in rheumatoid arthritis patients
by: Samimi Z, et al.
Published: (2019-07-01)

Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta-analysis
by: D. Vinson, et al.
Published: (2020-04-01)

Randomised, Double-Blind, Placebo-Controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis
by: Yan Li, et al.
Published: (2021-06-01)

Treatment of Rheumatoid Arthritis with Methotrexate Alone or A Combination of Methotrexate and Hydroxychloroquine
by: Natharubini Nadarajah, et al.
Published: (2016-09-01)

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
by: George W. Reed, et al.
Published: (2019-11-01)

A Systematic Review to Identify the Effects of Biologics in the Feet of Patients with Rheumatoid Arthritis
by: Laura Ramos-Petersen, et al.
Published: (2021-12-01)